Participants' assessment of improvement of pain in right TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in right TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of right masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of right masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Participants' assessment of global function (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) showed no clear difference in participants' assessment of global function (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Number of tender sites on muscles of mastication (palpation index) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower number of tender sites on muscles of mastication (palpation index) compared with placebo; GRADE not reported.
1 finding from 1 review
Spontaneous pain in the TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral gabapentin (anticonvulsant) led to lower spontaneous pain in the TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Jaw pain (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in jaw pain (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Participants' assessment of improvement of pain in left TMJ (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in participants' assessment of improvement of pain in left TMJ (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Pain on palpation of left masseter muscle (VAS) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral clonazepam (benzodiazepine) showed no clear difference in pain on palpation of left masseter muscle (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral celecoxib (COX-2 inhibitor) showed no clear difference in pain intensity (VAS) compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Ta and Dionne 2004 (celecoxib) reported adverse effects. Per the review: 'All but one study (Lobo et al 2004) reported adverse effects. Most of the reported adverse effects were mild and similar to the adverse effects…
1 study · 68 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review